Kinetics of B Cell Response in Infants Menjugate Vaccination

Novartis

Status and phase: Completed; Phase 4

Conditions: Prevention of Meningococcal Infection

Treatments: Biological: Meningococcal C conjugate vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00310700

Impact N° 1457

M14P5

2004-004962-33 (EudraCT Number)

Details and patient eligibility

About

Kinetics of B cell response in infants Menjugate vaccination

Sex: All

Ages: 8 to 11 weeks old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy infants

Exclusion criteria

• previously ascertained or suspected disease caused by N. meningitidis
• previous household contact with an individual with a positive culture of N. meningitidis serogroup C

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)